There is a great need for sensitive, precise, and easily accessible analytical detection techniques for protein sequencing.

Biologics Quality Control: The Growing Need for Accessible Proteomics

The emergence of mRNA vaccines and cell and gene therapies has pushed innovation in analytical methods.

Emerging Therapies Drive Analytical Advancements

Effective analytics will eliminate failures, deviations, and non-conformances.

 Analyzing Exabytes

Topic

Articles

ABEC, an equipment and engineering company, will provide a custom-made, single-use bioreactor to custom manufacturing firm, Emergent, for its Maryland manufacturing facility. 

ABEC Develops Single-Use Bioreactor for Emergent Manufacturing Facility

The biopharmaceutical company has received a $4.2-million grant from the Bill & Melinda Gates Foundation to invest in the development of new treatments for Enterotoxigenic Escherichia coli infections, a bacterial cause of diarrhea in the developing world.

Ventria Bioscience Receives $4.2-Million Grant for Intestinal Infection Treatments

The $72-million investment, part of a larger $850-million investment into its US operations, will allow the drugmaker to replace an outdated insulin vial-filling line and to upgrade technology at its Indianapolis manufacturing plant.

Lilly to Invest $72 Million for Insulin Manufacturing Upgrade

This approval marks the second gene therapy to be approved by FDA and the first to be approved for certain types of non-Hodgkin lymphoma.

FDA Approves Kite’s CAR-T Drug, Second Gene-Therapy in US

The companies aim to use CureVac’s proprietary messenger RNA technology to develop and commercialize up to five potential cancer vaccine products.

Lilly and CureVac Partner on mRNA Cancer Vaccines in $1.8-Billion Deal

The new center will serve as a regional hub where scientists and engineers can work with customers for biological development.

Merck KGaA Opens New Life Sciences Center

Stelara (ustekinumab), already approved for treating adults, is now also approved for treating adolescents with moderate to severe plaque psoriasis.

FDA Expands Approval for J&J’s Psoriasis Biologic

The vaccine is a non-live, recombinant subunit vaccine that combines an antigen and an adjuvant system to trigger a targeted and long-lasting immune response to the shingle-causing virus.

GSK’s Shingles Vaccine Approved in Canada

The company announced plans to expand its viral vector process development facilities in the United States and its cleanroom facilities in the Netherlands for vector-based products.

Batavia Biosciences Expands Viral Vector Facilities

Samsung BioLogics’ second facility adds 152,000 L of mAb drug substance capacity. 

Analytics

Biologics Quality Control: The Growing Need for Accessible Proteomics

Emerging Therapies Drive Analytical Advancements

Analyzing Exabytes